OOIR: Observatory of International Research

Papers

(The median citation count of Current Hematologic Malignancy Reports is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Targeting RUNX1 Germline Variants: Agents Under Investigation	183
Monoclonal Gammopathy-Associated Neuropathy	30
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations	25
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions	25
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations	25
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications	22
Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities	22
Management of Chronic Myeloid Leukemia in Children and Young Adults	21
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease	20
Value in Myeloma Care: Myth or Reality	19
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer	18
Splicing Factor Mutations in Chronic Myelomonocytic Leukemia: Biological Consequences and Therapeutic Implications	18
Allogeneic Transplant for CMML	17
Prognostic and Predictive Models in Myelofibrosis	16
Transplantation and Cellular Therapy for Older Adults—The MSK Approach	16
Multiple Myeloma: Current Clinical Landscape and Compounding Costs	15
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications	15
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders	14
How Do We Manage Chronic Lymphocytic Leukemia in India	13
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia	12
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies	12
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia	12
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults	11
Impact of Germline DNA Repair Mutations on Clonal Hematopoiesis and Myeloid Neoplasm Development	11
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders	10

Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma	9
Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia	9
Impact of Epigenetic Mutations in Chronic Myelomonocytic Leukemia	8
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia	8
Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders	8
Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes	8
CAR-T Cell Therapy: the Efficacy and Toxicity Balance	8
Pediatric Germline Predisposition to Myeloid Neoplasms	7
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms	7
Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation	7
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma	7
Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas	7
Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera	7
The Evolving Therapeutic Landscape of Richter Transformation	6
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals	6
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms	6
Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication	6
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)	6
Measurable Residual Disease Monitoring in Lymphoma	6
JAK Inhibitors for Myelofibrosis: Strengths and Limitations	6
Real-world Management of CML: Outcomes and Treatment Patterns	5
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors	5
Plasmacytoid Dendritic Cell-Expansion in Acute Myeloid Leukemia (pDC‑AML): a Review of Clinicopathologic Features, Genetics, and Outcomes	5
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases	5
Managing Survivorship after Hematopoietic Cell Transplantation	5
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors	5
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition	5